(Q24236740)

1

0 references

Fulco Van der Veen

6

0 references

author name string

Irene Kwan

2

0 references

Anna L Burt

3

0 references

Jane Thomas

4

0 references

Andy Vail

5

0 references

Hesham G Al-Inany

Cochrane Database of Systematic Reviews

7

0 references

language of work or name

English

0 references

publication date

16 February 2011

0 references

published in

0 references

issue

2

0 references

page(s)

CD005354

0 references

cites work

Efficacy of recombinant versus human derived follicle stimulating hormone on the oocyte and embryo quality in IVF-ICSI cycles: Randomised, controlled, multi-centre trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-beta for in vitro fertilization: a prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Highly purified human-derived follicle-stimulating hormone (Bravelle) has equivalent efficacy to follitropin-beta (Follistim) in infertile women undergoing in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

21 January 2018

Female poor responders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

A prospective and randomized study of ovarian stimulation for ICSI with recombinant FSH versus highly purified urinary FSH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Urinary follicle-stimulating hormone (FSH) is more effective than recombinant FSH in older women in a controlled randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

The effect of HMG and recombinant human FSH on oocyte quality: a randomized single-blind clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Effect of highly purified urinary follicle-stimulating hormone on oocyte and embryo quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Efficacy of a combined protocol of urinary and recombinant follicle-stimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Common statistical errors in the design and analysis of subfertility trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005354.PUB2

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial

21 January 2018

1 reference

12 December 2020

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Comparison of recombinant and urinary follicle-stimulating hormone preparations in short-term gonadotropin releasing hormone agonist protocol for in vitro fertilization-embryo transfer

1 reference

12 December 2020

Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.

1 reference

12 December 2020

Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. II. Comparison of hMG and recombinant FSH

1 reference

12 December 2020

Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Recombinant Human FSH Study Group

1 reference

12 December 2020

Recombinant FSH vs. urinary FSH for ovarian stimulation in in vitro fertilization.

1 reference

12 December 2020

Meta-analysis of recombinant versus urinary-derived FSH: an update

1 reference

12 December 2020

Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis

1 reference

12 December 2020

Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a

1 reference

12 December 2020

A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian

1 reference

12 December 2020